ADMA Biologics Inc (ADMA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ADMA Biologics Inc (ADMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9860
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ADMA Biologics Inc (ADMA Biologics) is an integrated biopharmaceutical and specialty immunoglobulin company that develops, produces, and commercializes specialty biologics to treat immune deficiencies and prevent certain infectious diseases. The company develops RI-002, is a specialty plasma-derived, polyclonal, intravenous immune globulin, derived from human plasma containing naturally occurring polyclonal antibodies to treat Primary Immune Deficiency Disease. ADMA Biologics’ target treatment areas include bacterial infections, respiratory syncytial virus and primary immune deficiency diseases. It also operates bio centers which carry out plasma collection and offer blood plasma to manufacture the company’s products. ADMA Biologics is headquartered in Ramsey, New Jersey, the US.

ADMA Biologics Inc (ADMA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADMA Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
ADMA Biologics Acquires Certain Assets from Biotest Pharma 11
Venture Financing 13
ADMA Biologics Secures USD20 Million from Oxford Finance 13
Adma Biologics Secures USD5 Million from Hercules 14
ADMA Biologics Secures Venture Funding from Biomark Capital 16
ADMA Plasma Biologics Raises US$17.6 Million In Venture Financing 17
Licensing Agreements 18
Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 18
Adma Biologics Amends Licensing Agreement With Biotest For IGIV 19
Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20
Equity Offering 21
ADMA Biologics Raises USD40 Million in Public Offering of Shares 21
ADMA Biologics to Raise Funds through Public Offering of Shares 23
ADMA Biologics Raises USD42 Million in Public Offering of Shares 24
ADMA Biologics Plans to Raise Funds through Secondary Offering of Shares 26
ADMA Biologics Raises USD14 Million in Public Offering of Shares 28
ADMA Biologics Raises USD11.2 Million in Public Offering of Shares 30
ADMA Biologics Completes IPO For US$28.5 Million 32
ADMA Biologics Raises USD17.6 Million in Private Placement of Shares 33
Acquisition 35
R&R Acquisition Acquires ADMA Biologics In Reverse Acquisition 35
ADMA Biologics Inc – Key Competitors 36
ADMA Biologics Inc – Key Employees 37
ADMA Biologics Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 10, 2018: ADMA Biologics reports second quarter 2018 financial results 39
May 14, 2018: ADMA Biologics Reports First Quarter 2018 Financial Results 41
Mar 05, 2018: ADMA Biologics Announces Full Year 2017 Financial Results 42
Nov 03, 2017: ADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial Results 43
Aug 11, 2017: ADMA Biologics Provides Corporate Update and Reports Second Quarter 2017 Financial Results 45
May 12, 2017: ADMA Biologics Provides Corporate Update and Reports First Quarter 2017 Financial Results 47
Feb 24, 2017: ADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones 48
Legal and Regulatory 49
Jul 26, 2018: Adma Biologics reports successful close-out of its April 2018 FDA compliance inspection 49
Other Significant Developments 50
Jun 27, 2017: ADMA Biologics Provides Corporate Timeline and Activities Update to Stockholders 50
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADMA Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADMA Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ADMA Biologics Acquires Certain Assets from Biotest Pharma 11
ADMA Biologics Secures USD20 Million from Oxford Finance 13
Adma Biologics Secures USD5 Million from Hercules 14
ADMA Biologics Secures Venture Funding from Biomark Capital 16
ADMA Plasma Biologics Raises US$17.6 Million In Venture Financing 17
Adma Biologics Enters Into Licensing Agreement With Biotest Pharma For RSV Immune Globulin 18
Adma Biologics Amends Licensing Agreement With Biotest For IGIV 19
Adma Biologics Enters Into Licensing Agreement With Biotest For Varicella Zoster Immune Globulin 20
ADMA Biologics Raises USD40 Million in Public Offering of Shares 21
ADMA Biologics to Raise Funds through Public Offering of Shares 23
ADMA Biologics Raises USD42 Million in Public Offering of Shares 24
ADMA Biologics Plans to Raise Funds through Secondary Offering of Shares 26
ADMA Biologics Raises USD14 Million in Public Offering of Shares 28
ADMA Biologics Raises USD11.2 Million in Public Offering of Shares 30
ADMA Biologics Completes IPO For US$28.5 Million 32
ADMA Biologics Raises USD17.6 Million in Private Placement of Shares 33
R&R Acquisition Acquires ADMA Biologics In Reverse Acquisition 35
ADMA Biologics Inc, Key Competitors 36
ADMA Biologics Inc, Key Employees 37
ADMA Biologics Inc, Subsidiaries 38

List of Figures
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ADMA Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ADMA Biologics Inc (ADMA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Molex LLC:企業のM&A・事業提携・投資動向
    Molex LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Molex LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Origin Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Origin Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Origin Energy Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the …
  • Kaiser Foundation Health Plan Inc:企業の戦略的SWOT分析
    Kaiser Foundation Health Plan Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Islet Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Islet Sciences Inc (Islet Sciences) is a drug development company that develops medicines and technologies for the treatment of metabolic diseases. The company's pipeline products include immune modulating small molecule interleukin 12 inhibitors to address disorders associated with inflamma …
  • Tendril Networks, Inc.:電力:M&Aディール及び事業提携情報
    Summary Tendril Networks, Inc. (Tendril) is a provider of cloud-based energy services management solutions. The company offers Energy Services Management platform that helps energy service providers meet energy efficiency goals across various channels including web, mobile, mail, and email; to enhan …
  • Vedanta Resources Ltd:企業の戦略的SWOT分析
    Vedanta Resources Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • TeleTech Holdings, Inc. (TTEC):企業の財務・戦略的SWOT分析
    TeleTech Holdings, Inc. (TTEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Hooper Holmes Inc (HH)-製薬・医療分野:企業M&A・提携分析
    Summary Hooper Holmes Inc (Hooper Holmes) is a provider of health and screening services. The company provides health services such as individual screenings at home or work, onsite screenings for small and large companies, remote screenings for individuals and eligible family members, convenient wal …
  • SK E&S Co Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary SK E&S Co Ltd (SK E&S) a subsidiary of SK Holdings Co Ltd is a utility service provider that offers natural gas and electricity distribution. The company’s business activities include city gas, district energy, power, overseas business and LNG. It operates and supplies electricity from its L …
  • BrainCool AB (BRAIN):医療機器:M&Aディール及び事業提携情報
    Summary BrainCool AB (BrainCool), a subsidiary of Dignitana AB, is a medical device company that focuses on developing, and commercializing medical cooling systems for brain cooling and pain management. The company’s products are based on the principle that applying therapeutic hypothermia contribut …
  • Honshu Chemical Industry Co Ltd (4115):企業の財務・戦略的SWOT分析
    Honshu Chemical Industry Co Ltd (4115) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Enel SpA (ENEL)-エネルギー分野:企業M&A・提携分析
    Summary Enel S.p.A. (Enel) is an energy group that produces, distributes and trades electricity and natural gas. The group generates electricity using diverse sources of energy such as nuclear, renewables, oil and gas turbine, coal and gas combined cycle. It also focuses on digitizing electricity gr …
  • Europlasma SA (ALEUP):企業の財務・戦略的SWOT分析
    Europlasma SA (ALEUP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • ChemoCentryx Inc (CCXI):企業の財務・戦略的SWOT分析
    Summary ChemoCentryx Inc (ChemoCentryx) is a bio pharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases and inflammatory disorders. The company's lead drug candidate include Avacopan, an orally-administered …
  • NetSol Technologies, Inc. (NTWK):企業の財務・戦略的SWOT分析
    NetSol Technologies, Inc. (NTWK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • RhythmOne plc:企業のM&A・事業提携・投資動向
    RhythmOne plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's RhythmOne plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Semiconductor Manufacturing International Corporation
    Semiconductor Manufacturing International Corporation - Strategy, SWOT and Corporate Finance Report Summary Semiconductor Manufacturing International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Nexter Group:企業の戦略・SWOT・財務情報
    Nexter Group - Strategy, SWOT and Corporate Finance Report Summary Nexter Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Inception Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Inception Sciences Inc (Inception Sciences) is a pharmaceutical company that offers drug discovery incubators. The company develops new companies in partnership with academic researchers and biopharmaceutical companies. It develops drugs for various indications such as fibrotic diseases, onc …
  • Aspyrian Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Aspyrian Therapeutics Inc (Aspyrian Therapeutics) is a biotechnology company which develops precision targeted medicines to handle both the primary tumor and systemic disease. Its lead pipeline product, RM-1929, is under development for the treatment of different cancer types, including canc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆